Lakewood-Amedex Biotherapeutics Awarded New Australian Patent Protecting Bisphosphocin Compounds That Are Being Explored In A Range Of Antimicrobial Infections

Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", ))), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the expansion of the Company's patent portfolio with the issuance of a new patent in Australia protecting Bisphosphocin® compounds that are being explored in a range of antimicrobial infections including complicated urinary tract infections and pulmonary infections.

The patent, titled, "Antimicrobial Compounds, Compositions, and Uses Thereof," was issued March 5, 2026, by IP Australia. Lakewood-Amedex Biotherapeutics' intellectual property portfolio is currently comprised of 72 granted patents and 29 pending patents in multiple countries and regions, including the United States, the European Patent Office, China, India, Japan, Mexico, Hong Kong, Republic of Korea, Brazil, United Kingdom, New Zealand, and Australia.

"This newly issued patent adds to our international intellectual property portfolio covering composition of matter patents for the Bisphosphocin® class of compounds," said Kelvin Cooper, Chief Executive Officer of Lakewood-Amedex Biotherapeutics. "Antimicrobial resistance (AMR) is a global crisis that is directly responsible for more than a six million deaths annually. As we work to deliver innovative antimicrobial solutions designed to tackle the challenges of AMR, our substantial IP foundation enhances our ability to bring solutions to the millions of patients in need, while potentially generating value for our shareholders."